Evidence map›Paper›PMID 40433841›Full record

ArticleBiotechnology and applied biochemistry2025

The Stem Cell Transcription Factor OCT4 Silences Target DNA Methyltransferase 1 to Strengthen DNA Damage Response in Cisplatin-Treated Gastric Cancer Cells.

Zhengzheng Yan, Xiaoqian Bu, Haixia Chen, Chongren Ren, Ji Li, Yongjie Wu, Jun Xing

Abstract read
In one paragraph

Article in Biotechnology and applied biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhengzheng YanGeneral Surgery Department, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 LongCheng Street, Taiyuan, Shanxi, China.
Xiaoqian BuThe Department of Tumor Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 LongCheng Street, Taiyuan, Shanxi, China.
Haixia ChenGeneral Surgery Department, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 LongCheng Street, Taiyuan, Shanxi, China.
Chongren RenGeneral Surgery Department, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 LongCheng Street, Taiyuan, Shanxi, China.
Ji LiGeneral Surgery Department, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 LongCheng Street, Taiyuan, Shanxi, China.
Yongjie WuGeneral Surgery Department, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 LongCheng Street, Taiyuan, Shanxi, China.
Jun XingDepartment of Breast Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 LongCheng Street, Taiyuan, Shanxi, China.ORCID https://orcid.org/0009-0007-4334-4347

Funding

Shanxi Science and Technology Department 202303021221199
6 · The paper itself

Abstract

OCT4 plays a crucial role in the DNA damage response(DDR) mechanism, whereas cisplatin (CDDP) acts as an anti-tumor agent by inducing DDR. This study aimed to investigate the role of OCT4 in regulating DNA methyltransferase 1 (DNMT1) in CDDP-treated gastric cancer (GC). A dual-luciferase reporter assay was performed to detect the relationship between DNMT1 and OCT4. Human GC cell lines HGC-27 and MGC-803 were transfected with siRNA-OCT4 or ov-DNMT1 to construct interfering cell lines; CDDP of 0, 2.5, 5, 10, and 20 µM was used to treat GC cell lines, respectively. As follows, γ-H2AX immunofluorescence was used to detect DDR. The protein expressions of OCT4 and DNMT1 were detected by Western blot (WB), and the effects of CDDP treatment on cell apoptosis and proliferation were assessed using CCK8, cell cloning, and flow cytometry. The IC50 of CDDP-treated GC cells was reduced by OCT4 silence but enhanced by DNMT1 overexpression. A targeted regulatory relationship exists between OCT4 and DNMT1. The expression of OCT4 and DNMT1 was increased in CDDP-treated cells, and DNMT1 was decreased in the siRNA-OCT4 group. In the CDDP-treated GC cells, DNMT1 overexpression significantly reversed the siRNA-OCT4-induced cell apoptosis, γ-H2AX upregulation, and proliferation decrease. OCT4 silence may target DNMT1 to induce DDR in GC cells to strengthen the CDDP-induced cell apoptosis and proliferation inhibition.

Indexed as

Antineoplastic AgentsCisplatinDNA (Cytosine-5-)-Methyltransferase 1DNA DamageGene SilencingOctamer Transcription Factor-3Stomach NeoplasmsApoptosisCell Line, TumorCell ProliferationHumansAntineoplastic AgentsCisplatinDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanOctamer Transcription Factor-3POU5F1 protein, humancisplatinDNA damage responseDNA methyltransferase 1 (DNMT1)drug resistancegastric cancerOCT4

Identifiers

PMID40433841
PMCPMC12687678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.